SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXPRNewsWire • 03/12/24
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTXAccesswire • 03/05/24
ATTENTION Repare Therapeutics Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 02/28/24
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 02/28/24
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - RPTXAccesswire • 02/27/24
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/20/24
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)Business Wire • 02/16/24
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/13/24
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone PaymentBusiness Wire • 01/25/24
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 MilestonesBusiness Wire • 01/08/24
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in CancerBusiness Wire • 01/04/24
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in CancerBusiness Wire • 01/04/24
Repare Therapeutics Insiders Establish Automatic Securities Disposition PlansBusiness Wire • 12/29/23
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ InhibitorBusiness Wire • 11/15/23
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsBusiness Wire • 11/09/23
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with CamonsertibBusiness Wire • 10/13/23
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a TurnaroundZacks Investment Research • 10/11/23
Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 WeeksZacks Investment Research • 10/09/23
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 10/03/23